Search results
Results from the WOW.Com Content Network
Febuxostat, sold under the brand name Uloric among others, is a medication used long-term to treat gout due to high uric acid levels. [7] It is generally recommended only for people who cannot take allopurinol .
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB .
A xanthine oxidase inhibitor is any substance that inhibits the activity of xanthine oxidase, an enzyme involved in purine metabolism.In humans, inhibition of xanthine oxidase reduces the production of uric acid, and several medications that inhibit xanthine oxidase are indicated for treatment of hyperuricemia and related medical conditions including gout. [1]
An illustrative diagram explaining drug resistance. Drug resistance is the reduction in effectiveness of a medication such as an antimicrobial or an antineoplastic in treating a disease or condition. [1] The term is used in the context of resistance that pathogens or cancers have "acquired", that is, resistance has evolved.
Generally, drugs outlined within the ATC code M04 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antigout agents .
Image source: The Motley Fool. AbbVie (NYSE: ABBV) Q4 2024 Earnings Call Jan 31, 2025, 9:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not effective or are not tolerated. [2] The drug is administered by infusion intravenously. Since October 2023, Amgen Inc. has been the marketer of pegloticase in ...